BELLUS Health Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, announced that Roberto Bellini, BELLUS Health’s President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference.
LAVAL, Quebec--(BUSINESS WIRE)-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health’s President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference.
Presentation Details:
Event: Jefferies Virtual Healthcare Conference
Date: Tuesday, June 2, 2020
Time: 1:30 p.m. EDT
A live webcast of the fireside chat may be accessed on the Events and Presentations page under the Investors & News section of BELLUS Health’s website at www.bellushealth.com. Following the event, an archived webcast will be available on the Company’s website.
About BELLUS Health
BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company’s product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200528005137/en/
Danny Matthews
Director, Investor Relations and Communications
917-828-0414
danny@bellushealth.com
Source: BELLUS Health Inc.
View this news release online at:
http://www.businesswire.com/news/home/20200528005137/en
